7, Sangdo-ro, Dongjak-gu, Seoul, Korea 06955   Tel : 02)8288-114   Fax : 02)8288-029   CS : 02)8288-114

Copyright © 2015 Bukwang Pharmaceutical Co., Ltd.All Rights Reserved.

  • Facebook Basic Square
  • Google+ Basic Square

MLR-1023: insulin sensitizing agent

  • MLR-1023 is a new drug discovered through drug repositioning technology. It is a novel candidate for type 2 diabetes, lowering blood glucose level by activating the Lyn kinase that controls insulin signalling pathway.

 

  • MLR-1023 was found to have excellent anti-diabetic efficacy without adverse effects such as weight gain in several preclinical models. Also, protective effect on beta cells in pancreas was also observed.

 

  • Bukwang and US based pharmaceutical company, Melior Pharmaceuticals I. Inc, are co-developing MLR-1023. MLR-1023 is now under global phase 2b study in both US and Korea and it is expected to complete in 2018 and to have result in the first half of 2019.

|    ​Korean    |